Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
about
From bench to clinic and back: Perspective on the 1st IQPC Translational Research conferenceThe Nuremberg Code subverts human health and safety by requiring animal modelingAnimal models and conserved processesAnalytical validation of accelerator mass spectrometry for pharmaceutical developmentOpportunities in low-level radiocarbon microtracing: applications and new technologyUse of Accelerator Mass Spectrometry in Human Health and Molecular ToxicologyModeling of PET data in CNS drug discovery and development.The use of pharmacokinetic and pharmacodynamic data in the assessment of drug safety in early drug developmentRecent advances in pharmacokinetic extrapolation from preclinical data to humans.The use of accelerator mass spectrometry to obtain early human ADME/PK data.Use of the optogalvanic effect (OGE) for isotope ratio spectrometry of 13CO2 and 14CO2.Intracavity optogalvanic spectroscopy. An analytical technique for 14C analysis with subattomole sensitivity.Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.Accelerator mass spectrometry-enabled studies: current status and future prospects.Phase 0 clinical trials: recommendations from the Task Force on Methodology for the Development of Innovative Cancer TherapiesFood and drug administration's critical path initiative and innovations in drug development paradigm: Challenges, progress, and controversies.Dose selection method for pharmacokinetic study in hemodialysis patients using a subpharmacological dose: oseltamivir as a model drug.Phase 0 Workshop at the 20th EORTC-NCI-AACR Symposium, Geneva.Molecular Imaging of Membrane Transporters' Activity in Cancer: a Picture is Worth a Thousand Tubes.Observational infant exploratory [(14)C]-paracetamol pharmacokinetic microdose/therapeutic dose study with accelerator mass spectrometry bioanalysis.Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.Novel insights in drug metabolism by MS imaging.Microdosing and drug development: past, present and futureSingle and multiple dose intravenous and oral pharmacokinetics of the hedgehog pathway inhibitor vismodegib in healthy female subjectsTargeted molecular imaging in oncology: focus on radiation therapy.The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trialsIntraarterial Microdosing: A Novel Drug Development Approach, Proof-of-Concept PET Study in Rats.Functional PET imaging in cancer drug development.The conduct of drug metabolism studies considered good practice (I): analytical systems and in vivo studiesRecent advances in biomedical applications of accelerator mass spectrometry.Drug metabolism and pharmacokinetics.Quantifying Carbon-14 for Biology Using Cavity Ring-Down Spectroscopy.Microdosing and Other Phase 0 Clinical Trials: Facilitating Translation in Drug Development.New ultrasensitive detection technologies and techniques for use in microdosing studies.Microdosing: current and the future.Microdosing studies using accelerated mass spectrometry as exploratory investigational new drug trials.Using high-resolution quadrupole TOF technology in DMPK analyses.The application of human phase 0 microdosing trials: A systematic review and perspectives.Phase-0/microdosing studies using PET, AMS, and LC-MS/MS: a range of study methodologies and conduct considerations. Accelerating development of novel pharmaceuticals through safe testing in humans - a practical guide.Preclinical safety assessments of nano-sized constructs on cardiovascular system toxicity: A case for telemetry.
P2860
Q24803350-43D9E82F-2EF8-4F0A-8A70-69FD4B5CF51AQ26866469-5BF7CAAA-40E5-425F-A02E-9406B018A8FAQ28710144-DD1F6EEE-7A2D-4E4D-B542-EB57C5498758Q28743669-7FAA3B34-CB75-4BFA-A9BB-D7BDCE446F0EQ28817904-932AF89D-69B1-4EB8-967E-6A8947008EF6Q28818313-12E5AB68-0C28-45AF-9648-918E88BC98D5Q30623699-5AD14813-8558-430C-9398-3269DFEC6799Q30977143-9E1A4B1B-AE50-4A00-AC85-80CCA6AA0D83Q31049599-BBDC0CF1-E144-4444-905E-B8623CF6C22CQ31055937-6829C807-424B-418A-A9A9-6D7C6F0B19E8Q33236819-68994B45-8270-4577-A6EF-92E9D1D2F303Q33340778-9E96BDC7-7AD3-44C1-B496-AA46A0EDF3CCQ33748891-067C8A84-B066-49F0-A948-1A08689C112CQ33819361-C8DA6E64-D0A1-4F2F-BAD1-4A50A9BED50FQ33985780-28D16B52-F0FA-4189-8682-18271E857510Q34373826-9C5C0D4A-C866-48A0-947E-45F59052B5BCQ35122440-626AF1FD-A384-4490-A13C-34E04E8BBB36Q35602195-851D2E06-CC98-4EE0-9A06-4135EC27A3DAQ35768413-3B5EE07A-1B6D-47F3-AB92-9195C0A79BC4Q35846147-AC580815-E93A-4D82-98DF-525970BEF610Q35884220-431325CF-A65D-42E4-84FE-EAD066E6FEDEQ35936145-7E522922-6F32-4020-B632-531214BD9AEBQ35940544-8F45B62C-6F8A-4591-AB3A-9B84884170F3Q36390239-25017BE3-33DC-4CCD-92FF-B39862BD9991Q36528175-6CCEBB60-6427-4FF2-8E67-3ADFAD2D9B3FQ36611045-E0A36E10-9CA7-46ED-A29A-4D7117BF9924Q36618309-CC0C9494-2708-43B7-A0BA-BBE9956C2E04Q36768305-B3BF917F-A8C3-4F19-B1C2-861A55A18C32Q37065418-FC90A3A2-62C5-4324-8064-9F674CADAC12Q37266360-785A469F-58F5-4F4D-B702-DB13B075D736Q37550548-F84B95FA-0E62-41F6-A7EB-07DC8EFBCB95Q37600860-703546D7-5E40-4393-BAC6-52F4A98ED48DQ37701128-04E59035-F6EF-49B2-BC8F-9F427238CF30Q37810198-8F74CF9F-62F8-44F4-9BCA-9747948E923EQ37810237-30A29656-C370-4FE3-BDDD-6A7ABCEDA184Q37964571-67E5C874-A0E3-49F2-BE84-8C1CFCD2D133Q37992702-1090901C-9CDB-4D84-8B03-0D3C089C9700Q38597205-A3FB9474-6563-46BA-9964-E09FCA00EE31Q38937832-91CD219D-083B-477E-AC4F-A0F3BD5678D3Q39121977-D35AABCE-81FA-4250-9871-DF92BB7AB6AB
P2860
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Big physics, small doses: the ...... rodosing of development drugs.
@ast
Big physics, small doses: the ...... rodosing of development drugs.
@en
type
label
Big physics, small doses: the ...... rodosing of development drugs.
@ast
Big physics, small doses: the ...... rodosing of development drugs.
@en
prefLabel
Big physics, small doses: the ...... rodosing of development drugs.
@ast
Big physics, small doses: the ...... rodosing of development drugs.
@en
P2860
P356
P1476
Big physics, small doses: the ...... rodosing of development drugs.
@en
P2093
Graham Lappin
R Colin Garner
P2860
P2888
P304
P356
10.1038/NRD1037
P577
2003-03-01T00:00:00Z